RS64792B1 - Derivati bicikličnih heteroarila kao inhibitori ektonukleotid pirofosfataze fosfodiesteraze 1 - Google Patents

Derivati bicikličnih heteroarila kao inhibitori ektonukleotid pirofosfataze fosfodiesteraze 1

Info

Publication number
RS64792B1
RS64792B1 RS20231040A RSP20231040A RS64792B1 RS 64792 B1 RS64792 B1 RS 64792B1 RS 20231040 A RS20231040 A RS 20231040A RS P20231040 A RSP20231040 A RS P20231040A RS 64792 B1 RS64792 B1 RS 64792B1
Authority
RS
Serbia
Prior art keywords
inhibitors
bicyclic heteroaryl
heteroaryl derivatives
ectonucleotide pyrophosphatase
pyrophosphatase phosphodiesterase
Prior art date
Application number
RS20231040A
Other languages
English (en)
Inventor
Ronald Hawley
Klaus Klumpp
Original Assignee
Riboscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riboscience Llc filed Critical Riboscience Llc
Publication of RS64792B1 publication Critical patent/RS64792B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20231040A 2019-04-12 2020-04-10 Derivati bicikličnih heteroarila kao inhibitori ektonukleotid pirofosfataze fosfodiesteraze 1 RS64792B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962833455P 2019-04-12 2019-04-12
US201962881111P 2019-07-31 2019-07-31
PCT/US2020/027700 WO2020210649A1 (en) 2019-04-12 2020-04-10 Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
EP20722196.1A EP3952995B1 (en) 2019-04-12 2020-04-10 Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors

Publications (1)

Publication Number Publication Date
RS64792B1 true RS64792B1 (sr) 2023-11-30

Family

ID=70465561

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20231040A RS64792B1 (sr) 2019-04-12 2020-04-10 Derivati bicikličnih heteroarila kao inhibitori ektonukleotid pirofosfataze fosfodiesteraze 1

Country Status (23)

Country Link
US (1) US20220362266A1 (sr)
EP (2) EP3952995B1 (sr)
JP (1) JP2022526432A (sr)
KR (1) KR20210151873A (sr)
CN (1) CN114040915A (sr)
AU (1) AU2020272034A1 (sr)
BR (1) BR112021020241A2 (sr)
CA (1) CA3136443A1 (sr)
DK (1) DK3952995T3 (sr)
ES (1) ES2960987T3 (sr)
FI (1) FI3952995T3 (sr)
HR (1) HRP20231413T1 (sr)
HU (1) HUE064377T2 (sr)
IL (1) IL286966A (sr)
LT (1) LT3952995T (sr)
MX (2) MX2021012305A (sr)
PL (1) PL3952995T3 (sr)
PT (1) PT3952995T (sr)
RS (1) RS64792B1 (sr)
SG (1) SG11202110888QA (sr)
SI (1) SI3952995T1 (sr)
TW (1) TW202103708A (sr)
WO (1) WO2020210649A1 (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204409A1 (en) * 2021-01-29 2022-08-04 Chan Sun Park Novel benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof
WO2022197734A1 (en) * 2021-03-16 2022-09-22 Riboscience Llc Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
CN116444544A (zh) * 2022-01-10 2023-07-18 中国科学院上海药物研究所 苯并咪唑类化合物及其医药用途
WO2024099907A1 (en) * 2022-11-09 2024-05-16 Boehringer Ingelheim International Gmbh Cyclic benzimidazole derivatives as cgas inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
US20090176849A1 (en) * 2005-05-24 2009-07-09 Lek Pharmaceuticals, D.D. Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives
CN100427488C (zh) * 2005-10-21 2008-10-22 上海东升新材料有限公司 腺嘌呤类衍生物及其合成方法
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP3246034A1 (en) * 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
EP2558577B1 (en) * 2010-04-16 2018-12-12 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
EP2710006A1 (en) * 2011-05-17 2014-03-26 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
WO2016055582A1 (en) * 2014-10-08 2016-04-14 Thomas Helledays Stiftelse För Medicinsk Forskning Heterocyclic compounds as dctpp1 modulators
ES2823049T3 (es) * 2015-07-31 2021-05-05 Pfizer Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-ilo y derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ilo como inhibidores de MAGL
CN110446503A (zh) * 2016-12-22 2019-11-12 马福制药公司 磷酸二酯酶抑制剂及微生物治疗方法
CA3047579A1 (en) * 2016-12-22 2018-06-28 Mavupharma, Inc. Compositions and methods of enhancing or augmenting type i ifn production
US10487084B2 (en) * 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
WO2019096113A1 (zh) * 2017-11-14 2019-05-23 深圳市塔吉瑞生物医药有限公司 一种氘代的含硼的化合物及药物组合物和用途

Also Published As

Publication number Publication date
SG11202110888QA (en) 2021-10-28
MX2023011065A (es) 2023-09-28
CA3136443A1 (en) 2020-10-15
EP4249070A2 (en) 2023-09-27
ES2960987T3 (es) 2024-03-07
KR20210151873A (ko) 2021-12-14
EP3952995B1 (en) 2023-09-20
US20220362266A1 (en) 2022-11-17
FI3952995T3 (fi) 2023-10-26
EP4249070A3 (en) 2024-04-17
WO2020210649A1 (en) 2020-10-15
DK3952995T3 (da) 2023-10-30
JP2022526432A (ja) 2022-05-24
TW202103708A (zh) 2021-02-01
HUE064377T2 (hu) 2024-03-28
EP3952995A1 (en) 2022-02-16
MX2021012305A (es) 2021-11-12
AU2020272034A1 (en) 2021-10-28
PT3952995T (pt) 2023-10-25
LT3952995T (lt) 2023-11-10
SI3952995T1 (sl) 2023-12-29
HRP20231413T1 (hr) 2024-02-16
CN114040915A (zh) 2022-02-11
PL3952995T3 (pl) 2024-03-11
BR112021020241A2 (pt) 2021-12-07
IL286966A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
IL286966A (en) History of bicyclic heteroaryls as ectonucleotide pyrophosphatase phosphodiesterase inhibitors
IL276509A (en) Heterocyclic compounds as kinase inhibitors
EP3902787A4 (en) QUINAZOLINE DERIVATIVES USED AS ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 INHIBITORS
SI3523301T1 (sl) Substituirane spojine pirazolo(1,5-A)piridina kot inhibitorji RET kinaze
IL290508A (en) Heterocyclic compounds as kinase inhibitors
SG11202011299PA (en) Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
EP4067359A4 (en) PYRIMIDOIMIDAZOLE COMPOUNDS AS DNA-PK INHIBITORS
SG11202013016YA (en) Heterocyclic compounds as trk inhibitors
EP3666770A4 (en) NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS
IL273443A (en) Bicyclic compounds for use as RIP1 kinase inhibitors
IL284767A (en) Heterocyclic compounds as adenosine antagonists
SG11202109781QA (en) Uses of phosphodiesterase inhibitors
IL289389A (en) Heterocyclic compounds as kinase inhibitors
IL284762A (en) Heterocyclic compounds as adenosine antagonists
SG11202008705TA (en) Heteroaryl compounds as kinase inhibitor
SG10202110112TA (en) Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
EP3844166C0 (en) SUBSTITUTED MACROCYCLES USEFUL AS KINASE INHIBITORS
IL291785A (en) 6,1- Naphthyridine-converted inhibitors of cdk5
SG11202102015QA (en) Fused ring derivative used as fgfr4 inhibitor
EA201692227A1 (ru) Производные сложных аминоэфиров
IL269144A (en) Pyrrolotriazine derivatives as kinase inhibitors
IL290314A (en) Quinolines as protein kinase inhibitors
ZA201908372B (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
IL291382A (en) 2-amino-6s-disubstituted thiopurine compounds as enpp1 protein inhibitors
EP3863638A4 (en) PHOSPHODIESTERASE INHIBITORS